APRA has been ordered to hand over all of its correspondence with fellow regulator ASIC relating to former IOOF chairman George Venardos, as he prepares to argue privilege over discovery that might incriminate him in any possible ASIC proceedings.
Multiple Canberra property developers have been accused of deliberately trying to avoid repaying GST to home buyers at the outset of a class action trial involving almost 500 apartment owners.
Generic pharmaceutical firm Sandoz has won a temporary stay of a $26.3 million judgment in a patent case as it awaits a decision by the Commissioner of Patents regarding a licence to make a cheaper version of the bestselling antidepressant Lexapro.
The trial in the ACCC’s case against hospital group Ramsay Health Care has doubled in length after the regulator made a late bid to enter as evidence a file note based on a sound recording of a meeting in which a Ramsay unit’s CEO allegedly made anti-competitive threats.
A surgeon who was considering opening a health clinic in Coffs Harbour, NSW recorded one of the meetings central to the competition watchdog’s action against Ramsay Health, in which alleged anti-competitive threats were made by a CEO of two Ramsay units, a court has heard.
Ramsay Health Care has denied its conduct towards a group of surgeons seeking to open a rival clinic in Coffs Harbour, NSW was anti-competitive or a misuse of market power, telling the court on the first day of trial that the venture was doomed to fail.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.
Pharmaceutical giant Wyeth has accused Merck Sharp & Dohme of a “baseless” patent invalidity case, saying on the second day of trial over the world’s best selling vaccine that the development of its patented Prevnar 13 pneumococcal shot was anything but obvious, as its rival contends.
A showdown between global pharmaceutical giants over the world’s best selling vaccine began Monday in Federal Court, with Merck Sharp & Dohme claiming three patents for Prevnar 13 sold by Pfizer’s Wyeth are invalid and that its own vaccine offers greater protection against pneumococcal bacteria.